lambda protein phosphatase buffer Search Results


97
New England Biolabs concentrated mncl 2 solution
Concentrated Mncl 2 Solution, supplied by New England Biolabs, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/concentrated mncl 2 solution/product/New England Biolabs
Average 97 stars, based on 1 article reviews
concentrated mncl 2 solution - by Bioz Stars, 2026-06
97/100 stars
  Buy from Supplier

97
New England Biolabs lambda phosphatase
( a ) Western blot analysis of SH-SY5Y cells primed for 16 h with IFN type I followed or not by treatment with Poly(I:C) (IFN/pIC) for 48 h using anti-MLKL, -RIPK3 and -actin antibodies. ( b and c ) MLKL was knocked out by CRISPR/Cas9 approach using two different gRNAs in SH-SY5Y cells. ( b ) Western blot analysis of MLKL expression levels using anti-MLKL and -actin antibodies treated with IFN for 16 h. ( c ) Cell death profile following IFN/pIC treatment for 48 h analyzing SytoxGreen (SG) positive cells. Data points represent the mean ± □S.E.M. of n = 3. **p = 0.009 and 0.0032. ( d ) Cell death profile analyzing PI positive SH-SY5Y cells, left untreated or treated for 48 h with IFN/pIC in combination with GSK-872’ (RIPK3i) or necrosulfonamide (NSA). Data points represent the mean ± S.E.M. of four independent experiments (n = 4); ***p=0.0004; ns= not significant. ( e ) Phostag SDS-Page of SH-SY5Y cells treated for indicated times with IFN/pIC or HT-29 cells with pBZ for 12 h to induce necroptosis using anti-p-MLKL (T357/S358) or anti-MLKL antibody. Phospho-MLKL bands were verified by <t>lambda</t> <t>phosphatase</t> treatment. A representative of n = 3 is shown. ( f ) Western blot analysis under non-reducing (-DTT) and reducing (+DTT) conditions of SH-SY5Y cells treated with IFN/pIC for the indicated times using an anti-MLKL antibody. A representative of n=3 is shown; left panel. Oligomeric MLKL is indicated. Right panel: Western blot analysis under non-reducing conditions of HT-29 cells treated with pBZ (poly(I:C), BV6 and zVAD-fmk; necroptosis (nec)) for 12 h using an anti-MLKL antibody. Oligomeric MLKL is indicated by an arrowhead. b: bottom of the well; i: interface between stacking and running gel. ( g ) Confocal images of MLKL-GFP expressing SH-SY5Y cells expressing LAMP-1-RFP and Hoechst left untreated or treated for 24 h with IFN/pIC. Merged image of MLKL-GFP, LAMP-1 and Hoechst right panel. Scale bars 10 µm. Representative images of n = 1 are shown. ( h ) Quantification of ( g ) analyzing the percentage of overlay of LAMP-1-RFP fluorescence intensity with MLKL-GFP. Data points represent the mean ± S.E.M. of n = 2 analyzing at least 25 cells. ****p < 0.0001.
Lambda Phosphatase, supplied by New England Biolabs, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/lambda phosphatase/product/New England Biolabs
Average 97 stars, based on 1 article reviews
lambda phosphatase - by Bioz Stars, 2026-06
97/100 stars
  Buy from Supplier

96
Santa Cruz Biotechnology calf intestinal phosphatase
( a ) Western blot analysis of SH-SY5Y cells primed for 16 h with IFN type I followed or not by treatment with Poly(I:C) (IFN/pIC) for 48 h using anti-MLKL, -RIPK3 and -actin antibodies. ( b and c ) MLKL was knocked out by CRISPR/Cas9 approach using two different gRNAs in SH-SY5Y cells. ( b ) Western blot analysis of MLKL expression levels using anti-MLKL and -actin antibodies treated with IFN for 16 h. ( c ) Cell death profile following IFN/pIC treatment for 48 h analyzing SytoxGreen (SG) positive cells. Data points represent the mean ± □S.E.M. of n = 3. **p = 0.009 and 0.0032. ( d ) Cell death profile analyzing PI positive SH-SY5Y cells, left untreated or treated for 48 h with IFN/pIC in combination with GSK-872’ (RIPK3i) or necrosulfonamide (NSA). Data points represent the mean ± S.E.M. of four independent experiments (n = 4); ***p=0.0004; ns= not significant. ( e ) Phostag SDS-Page of SH-SY5Y cells treated for indicated times with IFN/pIC or HT-29 cells with pBZ for 12 h to induce necroptosis using anti-p-MLKL (T357/S358) or anti-MLKL antibody. Phospho-MLKL bands were verified by <t>lambda</t> <t>phosphatase</t> treatment. A representative of n = 3 is shown. ( f ) Western blot analysis under non-reducing (-DTT) and reducing (+DTT) conditions of SH-SY5Y cells treated with IFN/pIC for the indicated times using an anti-MLKL antibody. A representative of n=3 is shown; left panel. Oligomeric MLKL is indicated. Right panel: Western blot analysis under non-reducing conditions of HT-29 cells treated with pBZ (poly(I:C), BV6 and zVAD-fmk; necroptosis (nec)) for 12 h using an anti-MLKL antibody. Oligomeric MLKL is indicated by an arrowhead. b: bottom of the well; i: interface between stacking and running gel. ( g ) Confocal images of MLKL-GFP expressing SH-SY5Y cells expressing LAMP-1-RFP and Hoechst left untreated or treated for 24 h with IFN/pIC. Merged image of MLKL-GFP, LAMP-1 and Hoechst right panel. Scale bars 10 µm. Representative images of n = 1 are shown. ( h ) Quantification of ( g ) analyzing the percentage of overlay of LAMP-1-RFP fluorescence intensity with MLKL-GFP. Data points represent the mean ± S.E.M. of n = 2 analyzing at least 25 cells. ****p < 0.0001.
Calf Intestinal Phosphatase, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/calf intestinal phosphatase/product/Santa Cruz Biotechnology
Average 96 stars, based on 1 article reviews
calf intestinal phosphatase - by Bioz Stars, 2026-06
96/100 stars
  Buy from Supplier

90
BioView Inc identified proteins (66/78) including 0 decoys
( a ) Western blot analysis of SH-SY5Y cells primed for 16 h with IFN type I followed or not by treatment with Poly(I:C) (IFN/pIC) for 48 h using anti-MLKL, -RIPK3 and -actin antibodies. ( b and c ) MLKL was knocked out by CRISPR/Cas9 approach using two different gRNAs in SH-SY5Y cells. ( b ) Western blot analysis of MLKL expression levels using anti-MLKL and -actin antibodies treated with IFN for 16 h. ( c ) Cell death profile following IFN/pIC treatment for 48 h analyzing SytoxGreen (SG) positive cells. Data points represent the mean ± □S.E.M. of n = 3. **p = 0.009 and 0.0032. ( d ) Cell death profile analyzing PI positive SH-SY5Y cells, left untreated or treated for 48 h with IFN/pIC in combination with GSK-872’ (RIPK3i) or necrosulfonamide (NSA). Data points represent the mean ± S.E.M. of four independent experiments (n = 4); ***p=0.0004; ns= not significant. ( e ) Phostag SDS-Page of SH-SY5Y cells treated for indicated times with IFN/pIC or HT-29 cells with pBZ for 12 h to induce necroptosis using anti-p-MLKL (T357/S358) or anti-MLKL antibody. Phospho-MLKL bands were verified by <t>lambda</t> <t>phosphatase</t> treatment. A representative of n = 3 is shown. ( f ) Western blot analysis under non-reducing (-DTT) and reducing (+DTT) conditions of SH-SY5Y cells treated with IFN/pIC for the indicated times using an anti-MLKL antibody. A representative of n=3 is shown; left panel. Oligomeric MLKL is indicated. Right panel: Western blot analysis under non-reducing conditions of HT-29 cells treated with pBZ (poly(I:C), BV6 and zVAD-fmk; necroptosis (nec)) for 12 h using an anti-MLKL antibody. Oligomeric MLKL is indicated by an arrowhead. b: bottom of the well; i: interface between stacking and running gel. ( g ) Confocal images of MLKL-GFP expressing SH-SY5Y cells expressing LAMP-1-RFP and Hoechst left untreated or treated for 24 h with IFN/pIC. Merged image of MLKL-GFP, LAMP-1 and Hoechst right panel. Scale bars 10 µm. Representative images of n = 1 are shown. ( h ) Quantification of ( g ) analyzing the percentage of overlay of LAMP-1-RFP fluorescence intensity with MLKL-GFP. Data points represent the mean ± S.E.M. of n = 2 analyzing at least 25 cells. ****p < 0.0001.
Identified Proteins (66/78) Including 0 Decoys, supplied by BioView Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/identified proteins (66/78) including 0 decoys/product/BioView Inc
Average 90 stars, based on 1 article reviews
identified proteins (66/78) including 0 decoys - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier

96
Santa Cruz Biotechnology ripa lysis buffer system santa cruz biotech cat
( a ) Western blot analysis of SH-SY5Y cells primed for 16 h with IFN type I followed or not by treatment with Poly(I:C) (IFN/pIC) for 48 h using anti-MLKL, -RIPK3 and -actin antibodies. ( b and c ) MLKL was knocked out by CRISPR/Cas9 approach using two different gRNAs in SH-SY5Y cells. ( b ) Western blot analysis of MLKL expression levels using anti-MLKL and -actin antibodies treated with IFN for 16 h. ( c ) Cell death profile following IFN/pIC treatment for 48 h analyzing SytoxGreen (SG) positive cells. Data points represent the mean ± □S.E.M. of n = 3. **p = 0.009 and 0.0032. ( d ) Cell death profile analyzing PI positive SH-SY5Y cells, left untreated or treated for 48 h with IFN/pIC in combination with GSK-872’ (RIPK3i) or necrosulfonamide (NSA). Data points represent the mean ± S.E.M. of four independent experiments (n = 4); ***p=0.0004; ns= not significant. ( e ) Phostag SDS-Page of SH-SY5Y cells treated for indicated times with IFN/pIC or HT-29 cells with pBZ for 12 h to induce necroptosis using anti-p-MLKL (T357/S358) or anti-MLKL antibody. Phospho-MLKL bands were verified by <t>lambda</t> <t>phosphatase</t> treatment. A representative of n = 3 is shown. ( f ) Western blot analysis under non-reducing (-DTT) and reducing (+DTT) conditions of SH-SY5Y cells treated with IFN/pIC for the indicated times using an anti-MLKL antibody. A representative of n=3 is shown; left panel. Oligomeric MLKL is indicated. Right panel: Western blot analysis under non-reducing conditions of HT-29 cells treated with pBZ (poly(I:C), BV6 and zVAD-fmk; necroptosis (nec)) for 12 h using an anti-MLKL antibody. Oligomeric MLKL is indicated by an arrowhead. b: bottom of the well; i: interface between stacking and running gel. ( g ) Confocal images of MLKL-GFP expressing SH-SY5Y cells expressing LAMP-1-RFP and Hoechst left untreated or treated for 24 h with IFN/pIC. Merged image of MLKL-GFP, LAMP-1 and Hoechst right panel. Scale bars 10 µm. Representative images of n = 1 are shown. ( h ) Quantification of ( g ) analyzing the percentage of overlay of LAMP-1-RFP fluorescence intensity with MLKL-GFP. Data points represent the mean ± S.E.M. of n = 2 analyzing at least 25 cells. ****p < 0.0001.
Ripa Lysis Buffer System Santa Cruz Biotech Cat, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ripa lysis buffer system santa cruz biotech cat/product/Santa Cruz Biotechnology
Average 96 stars, based on 1 article reviews
ripa lysis buffer system santa cruz biotech cat - by Bioz Stars, 2026-06
96/100 stars
  Buy from Supplier

93
Bethyl serum m protein levels
( a ) Western blot analysis of SH-SY5Y cells primed for 16 h with IFN type I followed or not by treatment with Poly(I:C) (IFN/pIC) for 48 h using anti-MLKL, -RIPK3 and -actin antibodies. ( b and c ) MLKL was knocked out by CRISPR/Cas9 approach using two different gRNAs in SH-SY5Y cells. ( b ) Western blot analysis of MLKL expression levels using anti-MLKL and -actin antibodies treated with IFN for 16 h. ( c ) Cell death profile following IFN/pIC treatment for 48 h analyzing SytoxGreen (SG) positive cells. Data points represent the mean ± □S.E.M. of n = 3. **p = 0.009 and 0.0032. ( d ) Cell death profile analyzing PI positive SH-SY5Y cells, left untreated or treated for 48 h with IFN/pIC in combination with GSK-872’ (RIPK3i) or necrosulfonamide (NSA). Data points represent the mean ± S.E.M. of four independent experiments (n = 4); ***p=0.0004; ns= not significant. ( e ) Phostag SDS-Page of SH-SY5Y cells treated for indicated times with IFN/pIC or HT-29 cells with pBZ for 12 h to induce necroptosis using anti-p-MLKL (T357/S358) or anti-MLKL antibody. Phospho-MLKL bands were verified by <t>lambda</t> <t>phosphatase</t> treatment. A representative of n = 3 is shown. ( f ) Western blot analysis under non-reducing (-DTT) and reducing (+DTT) conditions of SH-SY5Y cells treated with IFN/pIC for the indicated times using an anti-MLKL antibody. A representative of n=3 is shown; left panel. Oligomeric MLKL is indicated. Right panel: Western blot analysis under non-reducing conditions of HT-29 cells treated with pBZ (poly(I:C), BV6 and zVAD-fmk; necroptosis (nec)) for 12 h using an anti-MLKL antibody. Oligomeric MLKL is indicated by an arrowhead. b: bottom of the well; i: interface between stacking and running gel. ( g ) Confocal images of MLKL-GFP expressing SH-SY5Y cells expressing LAMP-1-RFP and Hoechst left untreated or treated for 24 h with IFN/pIC. Merged image of MLKL-GFP, LAMP-1 and Hoechst right panel. Scale bars 10 µm. Representative images of n = 1 are shown. ( h ) Quantification of ( g ) analyzing the percentage of overlay of LAMP-1-RFP fluorescence intensity with MLKL-GFP. Data points represent the mean ± S.E.M. of n = 2 analyzing at least 25 cells. ****p < 0.0001.
Serum M Protein Levels, supplied by Bethyl, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/serum m protein levels/product/Bethyl
Average 93 stars, based on 1 article reviews
serum m protein levels - by Bioz Stars, 2026-06
93/100 stars
  Buy from Supplier

99
Thermo Fisher tris hcl
( a ) Western blot analysis of SH-SY5Y cells primed for 16 h with IFN type I followed or not by treatment with Poly(I:C) (IFN/pIC) for 48 h using anti-MLKL, -RIPK3 and -actin antibodies. ( b and c ) MLKL was knocked out by CRISPR/Cas9 approach using two different gRNAs in SH-SY5Y cells. ( b ) Western blot analysis of MLKL expression levels using anti-MLKL and -actin antibodies treated with IFN for 16 h. ( c ) Cell death profile following IFN/pIC treatment for 48 h analyzing SytoxGreen (SG) positive cells. Data points represent the mean ± □S.E.M. of n = 3. **p = 0.009 and 0.0032. ( d ) Cell death profile analyzing PI positive SH-SY5Y cells, left untreated or treated for 48 h with IFN/pIC in combination with GSK-872’ (RIPK3i) or necrosulfonamide (NSA). Data points represent the mean ± S.E.M. of four independent experiments (n = 4); ***p=0.0004; ns= not significant. ( e ) Phostag SDS-Page of SH-SY5Y cells treated for indicated times with IFN/pIC or HT-29 cells with pBZ for 12 h to induce necroptosis using anti-p-MLKL (T357/S358) or anti-MLKL antibody. Phospho-MLKL bands were verified by <t>lambda</t> <t>phosphatase</t> treatment. A representative of n = 3 is shown. ( f ) Western blot analysis under non-reducing (-DTT) and reducing (+DTT) conditions of SH-SY5Y cells treated with IFN/pIC for the indicated times using an anti-MLKL antibody. A representative of n=3 is shown; left panel. Oligomeric MLKL is indicated. Right panel: Western blot analysis under non-reducing conditions of HT-29 cells treated with pBZ (poly(I:C), BV6 and zVAD-fmk; necroptosis (nec)) for 12 h using an anti-MLKL antibody. Oligomeric MLKL is indicated by an arrowhead. b: bottom of the well; i: interface between stacking and running gel. ( g ) Confocal images of MLKL-GFP expressing SH-SY5Y cells expressing LAMP-1-RFP and Hoechst left untreated or treated for 24 h with IFN/pIC. Merged image of MLKL-GFP, LAMP-1 and Hoechst right panel. Scale bars 10 µm. Representative images of n = 1 are shown. ( h ) Quantification of ( g ) analyzing the percentage of overlay of LAMP-1-RFP fluorescence intensity with MLKL-GFP. Data points represent the mean ± S.E.M. of n = 2 analyzing at least 25 cells. ****p < 0.0001.
Tris Hcl, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/tris hcl/product/Thermo Fisher
Average 99 stars, based on 1 article reviews
tris hcl - by Bioz Stars, 2026-06
99/100 stars
  Buy from Supplier

93
Proteintech goat serum
( a ) Western blot analysis of SH-SY5Y cells primed for 16 h with IFN type I followed or not by treatment with Poly(I:C) (IFN/pIC) for 48 h using anti-MLKL, -RIPK3 and -actin antibodies. ( b and c ) MLKL was knocked out by CRISPR/Cas9 approach using two different gRNAs in SH-SY5Y cells. ( b ) Western blot analysis of MLKL expression levels using anti-MLKL and -actin antibodies treated with IFN for 16 h. ( c ) Cell death profile following IFN/pIC treatment for 48 h analyzing SytoxGreen (SG) positive cells. Data points represent the mean ± □S.E.M. of n = 3. **p = 0.009 and 0.0032. ( d ) Cell death profile analyzing PI positive SH-SY5Y cells, left untreated or treated for 48 h with IFN/pIC in combination with GSK-872’ (RIPK3i) or necrosulfonamide (NSA). Data points represent the mean ± S.E.M. of four independent experiments (n = 4); ***p=0.0004; ns= not significant. ( e ) Phostag SDS-Page of SH-SY5Y cells treated for indicated times with IFN/pIC or HT-29 cells with pBZ for 12 h to induce necroptosis using anti-p-MLKL (T357/S358) or anti-MLKL antibody. Phospho-MLKL bands were verified by <t>lambda</t> <t>phosphatase</t> treatment. A representative of n = 3 is shown. ( f ) Western blot analysis under non-reducing (-DTT) and reducing (+DTT) conditions of SH-SY5Y cells treated with IFN/pIC for the indicated times using an anti-MLKL antibody. A representative of n=3 is shown; left panel. Oligomeric MLKL is indicated. Right panel: Western blot analysis under non-reducing conditions of HT-29 cells treated with pBZ (poly(I:C), BV6 and zVAD-fmk; necroptosis (nec)) for 12 h using an anti-MLKL antibody. Oligomeric MLKL is indicated by an arrowhead. b: bottom of the well; i: interface between stacking and running gel. ( g ) Confocal images of MLKL-GFP expressing SH-SY5Y cells expressing LAMP-1-RFP and Hoechst left untreated or treated for 24 h with IFN/pIC. Merged image of MLKL-GFP, LAMP-1 and Hoechst right panel. Scale bars 10 µm. Representative images of n = 1 are shown. ( h ) Quantification of ( g ) analyzing the percentage of overlay of LAMP-1-RFP fluorescence intensity with MLKL-GFP. Data points represent the mean ± S.E.M. of n = 2 analyzing at least 25 cells. ****p < 0.0001.
Goat Serum, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/goat serum/product/Proteintech
Average 93 stars, based on 1 article reviews
goat serum - by Bioz Stars, 2026-06
93/100 stars
  Buy from Supplier

99
New England Biolabs lic
Experimental results for exonuclease combinations treatment. ( A ) The cleavage mechanism of Lamada and Exonuclease I combinations. Other exonuclease combinations <t>(Lambda</t> and RecJF; Exonuclease I and Exonuclease III) are shown in and . ( B ) Three exonuclease combinations (LRL; LRC; <t>LIC)</t> removed linear DNA from a paradigm mixture. M, 1 kb DNA ladder; P, pGL4.23 plasmid; L, linearized plasmid; X, mixture (plasmid and linear DNA 1:1); 1-X, LRL-Mixture, LRL to cut mixture; 2-X, LRC-Mixture, LRC to cut mixture; 3-X, LIC-Mixture, LIC to cut mixture; 3-P, LIC to cut plasmid; 3-L, LIC-Lin, LIC to cut linearized plasmid; MS, supercoiled ladder. ( C ) I+III combination and Exonuclease VIII, truncated elimination tests. 5-X, VIII4-Mixture, Exonuclease VIII, truncated within Buffer 4 to remove mixture; 6-X, VIIIC-Mixture, Exonuclease VIII, truncated within CutSmart buffer to remove mixture; 4-X: I+III-Mixture, I+III to remove mixture. Loading samples for agarose gel electrophoresis were purified by phenol-chloroform.
Lic, supplied by New England Biolabs, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/lic/product/New England Biolabs
Average 99 stars, based on 1 article reviews
lic - by Bioz Stars, 2026-06
99/100 stars
  Buy from Supplier

96
Thermo Fisher ssc buffer 20x thermofisher scientific
Experimental results for exonuclease combinations treatment. ( A ) The cleavage mechanism of Lamada and Exonuclease I combinations. Other exonuclease combinations <t>(Lambda</t> and RecJF; Exonuclease I and Exonuclease III) are shown in and . ( B ) Three exonuclease combinations (LRL; LRC; <t>LIC)</t> removed linear DNA from a paradigm mixture. M, 1 kb DNA ladder; P, pGL4.23 plasmid; L, linearized plasmid; X, mixture (plasmid and linear DNA 1:1); 1-X, LRL-Mixture, LRL to cut mixture; 2-X, LRC-Mixture, LRC to cut mixture; 3-X, LIC-Mixture, LIC to cut mixture; 3-P, LIC to cut plasmid; 3-L, LIC-Lin, LIC to cut linearized plasmid; MS, supercoiled ladder. ( C ) I+III combination and Exonuclease VIII, truncated elimination tests. 5-X, VIII4-Mixture, Exonuclease VIII, truncated within Buffer 4 to remove mixture; 6-X, VIIIC-Mixture, Exonuclease VIII, truncated within CutSmart buffer to remove mixture; 4-X: I+III-Mixture, I+III to remove mixture. Loading samples for agarose gel electrophoresis were purified by phenol-chloroform.
Ssc Buffer 20x Thermofisher Scientific, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ssc buffer 20x thermofisher scientific/product/Thermo Fisher
Average 96 stars, based on 1 article reviews
ssc buffer 20x thermofisher scientific - by Bioz Stars, 2026-06
96/100 stars
  Buy from Supplier

Image Search Results


( a ) Western blot analysis of SH-SY5Y cells primed for 16 h with IFN type I followed or not by treatment with Poly(I:C) (IFN/pIC) for 48 h using anti-MLKL, -RIPK3 and -actin antibodies. ( b and c ) MLKL was knocked out by CRISPR/Cas9 approach using two different gRNAs in SH-SY5Y cells. ( b ) Western blot analysis of MLKL expression levels using anti-MLKL and -actin antibodies treated with IFN for 16 h. ( c ) Cell death profile following IFN/pIC treatment for 48 h analyzing SytoxGreen (SG) positive cells. Data points represent the mean ± □S.E.M. of n = 3. **p = 0.009 and 0.0032. ( d ) Cell death profile analyzing PI positive SH-SY5Y cells, left untreated or treated for 48 h with IFN/pIC in combination with GSK-872’ (RIPK3i) or necrosulfonamide (NSA). Data points represent the mean ± S.E.M. of four independent experiments (n = 4); ***p=0.0004; ns= not significant. ( e ) Phostag SDS-Page of SH-SY5Y cells treated for indicated times with IFN/pIC or HT-29 cells with pBZ for 12 h to induce necroptosis using anti-p-MLKL (T357/S358) or anti-MLKL antibody. Phospho-MLKL bands were verified by lambda phosphatase treatment. A representative of n = 3 is shown. ( f ) Western blot analysis under non-reducing (-DTT) and reducing (+DTT) conditions of SH-SY5Y cells treated with IFN/pIC for the indicated times using an anti-MLKL antibody. A representative of n=3 is shown; left panel. Oligomeric MLKL is indicated. Right panel: Western blot analysis under non-reducing conditions of HT-29 cells treated with pBZ (poly(I:C), BV6 and zVAD-fmk; necroptosis (nec)) for 12 h using an anti-MLKL antibody. Oligomeric MLKL is indicated by an arrowhead. b: bottom of the well; i: interface between stacking and running gel. ( g ) Confocal images of MLKL-GFP expressing SH-SY5Y cells expressing LAMP-1-RFP and Hoechst left untreated or treated for 24 h with IFN/pIC. Merged image of MLKL-GFP, LAMP-1 and Hoechst right panel. Scale bars 10 µm. Representative images of n = 1 are shown. ( h ) Quantification of ( g ) analyzing the percentage of overlay of LAMP-1-RFP fluorescence intensity with MLKL-GFP. Data points represent the mean ± S.E.M. of n = 2 analyzing at least 25 cells. ****p < 0.0001.

Journal: bioRxiv

Article Title: Lysosomal MLKL is balanced by ESCRT to control cell death

doi: 10.1101/2023.08.29.555049

Figure Lengend Snippet: ( a ) Western blot analysis of SH-SY5Y cells primed for 16 h with IFN type I followed or not by treatment with Poly(I:C) (IFN/pIC) for 48 h using anti-MLKL, -RIPK3 and -actin antibodies. ( b and c ) MLKL was knocked out by CRISPR/Cas9 approach using two different gRNAs in SH-SY5Y cells. ( b ) Western blot analysis of MLKL expression levels using anti-MLKL and -actin antibodies treated with IFN for 16 h. ( c ) Cell death profile following IFN/pIC treatment for 48 h analyzing SytoxGreen (SG) positive cells. Data points represent the mean ± □S.E.M. of n = 3. **p = 0.009 and 0.0032. ( d ) Cell death profile analyzing PI positive SH-SY5Y cells, left untreated or treated for 48 h with IFN/pIC in combination with GSK-872’ (RIPK3i) or necrosulfonamide (NSA). Data points represent the mean ± S.E.M. of four independent experiments (n = 4); ***p=0.0004; ns= not significant. ( e ) Phostag SDS-Page of SH-SY5Y cells treated for indicated times with IFN/pIC or HT-29 cells with pBZ for 12 h to induce necroptosis using anti-p-MLKL (T357/S358) or anti-MLKL antibody. Phospho-MLKL bands were verified by lambda phosphatase treatment. A representative of n = 3 is shown. ( f ) Western blot analysis under non-reducing (-DTT) and reducing (+DTT) conditions of SH-SY5Y cells treated with IFN/pIC for the indicated times using an anti-MLKL antibody. A representative of n=3 is shown; left panel. Oligomeric MLKL is indicated. Right panel: Western blot analysis under non-reducing conditions of HT-29 cells treated with pBZ (poly(I:C), BV6 and zVAD-fmk; necroptosis (nec)) for 12 h using an anti-MLKL antibody. Oligomeric MLKL is indicated by an arrowhead. b: bottom of the well; i: interface between stacking and running gel. ( g ) Confocal images of MLKL-GFP expressing SH-SY5Y cells expressing LAMP-1-RFP and Hoechst left untreated or treated for 24 h with IFN/pIC. Merged image of MLKL-GFP, LAMP-1 and Hoechst right panel. Scale bars 10 µm. Representative images of n = 1 are shown. ( h ) Quantification of ( g ) analyzing the percentage of overlay of LAMP-1-RFP fluorescence intensity with MLKL-GFP. Data points represent the mean ± S.E.M. of n = 2 analyzing at least 25 cells. ****p < 0.0001.

Article Snippet: For lambda phosphatase treatment cells were lysed in RIPA buffer and incubated with lambda phosphatase (New England biolabs; P0753S) for 30 min at 37 °C prior to TCA precipitation and loading on Phostag SDS-Page.

Techniques: Western Blot, CRISPR, Expressing, SDS Page, Fluorescence

Experimental results for exonuclease combinations treatment. ( A ) The cleavage mechanism of Lamada and Exonuclease I combinations. Other exonuclease combinations (Lambda and RecJF; Exonuclease I and Exonuclease III) are shown in and . ( B ) Three exonuclease combinations (LRL; LRC; LIC) removed linear DNA from a paradigm mixture. M, 1 kb DNA ladder; P, pGL4.23 plasmid; L, linearized plasmid; X, mixture (plasmid and linear DNA 1:1); 1-X, LRL-Mixture, LRL to cut mixture; 2-X, LRC-Mixture, LRC to cut mixture; 3-X, LIC-Mixture, LIC to cut mixture; 3-P, LIC to cut plasmid; 3-L, LIC-Lin, LIC to cut linearized plasmid; MS, supercoiled ladder. ( C ) I+III combination and Exonuclease VIII, truncated elimination tests. 5-X, VIII4-Mixture, Exonuclease VIII, truncated within Buffer 4 to remove mixture; 6-X, VIIIC-Mixture, Exonuclease VIII, truncated within CutSmart buffer to remove mixture; 4-X: I+III-Mixture, I+III to remove mixture. Loading samples for agarose gel electrophoresis were purified by phenol-chloroform.

Journal: Nucleic Acids Research

Article Title: Exonuclease combinations reduce noises in 3D genomics technologies

doi: 10.1093/nar/gkaa106

Figure Lengend Snippet: Experimental results for exonuclease combinations treatment. ( A ) The cleavage mechanism of Lamada and Exonuclease I combinations. Other exonuclease combinations (Lambda and RecJF; Exonuclease I and Exonuclease III) are shown in and . ( B ) Three exonuclease combinations (LRL; LRC; LIC) removed linear DNA from a paradigm mixture. M, 1 kb DNA ladder; P, pGL4.23 plasmid; L, linearized plasmid; X, mixture (plasmid and linear DNA 1:1); 1-X, LRL-Mixture, LRL to cut mixture; 2-X, LRC-Mixture, LRC to cut mixture; 3-X, LIC-Mixture, LIC to cut mixture; 3-P, LIC to cut plasmid; 3-L, LIC-Lin, LIC to cut linearized plasmid; MS, supercoiled ladder. ( C ) I+III combination and Exonuclease VIII, truncated elimination tests. 5-X, VIII4-Mixture, Exonuclease VIII, truncated within Buffer 4 to remove mixture; 6-X, VIIIC-Mixture, Exonuclease VIII, truncated within CutSmart buffer to remove mixture; 4-X: I+III-Mixture, I+III to remove mixture. Loading samples for agarose gel electrophoresis were purified by phenol-chloroform.

Article Snippet: After LRL (Lambda and RecJF within Lambda buffer) (NEB), LRC (Lambda and RecJF within Cutsmart buffer) (NEB), LIC (Lambda and Exonuclease I within Cutsmart buffer) (NEB) and I+IIIC (I+III or IIIIC) (Exonuclease I and Exonuclease III within Cutsmart buffer) (NEB) elimination, qPCR was performed.

Techniques: Plasmid Preparation, Agarose Gel Electrophoresis, Purification

Quantification effects for different combination treatments. ( A ) Results of every linear elimination treatment, measured by Qubit. Plasmid (250 ng) and linear DNA (250 ng) were mixed, as templates (X, Mixture). Linear DNA (500 ng) (3-L, LIC-Lin) was set as control treatments. Every treatment had three replicates. 1-X, LRL-Mixture; 2-X, LRC-Mixture; 3-X, LIC-Mixture; 4-X, I+III-Mixture; 5-X, VIII4-Mixture; 6-X, VIIIC-Mixture. ( B ) The qPCR results from three exonuclease combination treatments (in accordance with Figure ). The primer BH2 was used across the plasmid BamHI site. Same quality (SQ): The Qubit amounts of qPCR input for all treatments were consistent (Supplemental S.1.2). Same volume (SV): The qPCR input volumes were consistent (Supplemental S.1.4 and ). P, pGL4.23 plasmid; L, linearized plasmid; X, Mixture; 3-P, LIC to cut plasmid; 3-L, LIC to cut linearized plasmid. Three experiments for each treatment were combined for enlarging the volume before purification. ( C ) The qPCR results correspond with Figure . The primer was BH2. Data are presented as mean ± SEM.

Journal: Nucleic Acids Research

Article Title: Exonuclease combinations reduce noises in 3D genomics technologies

doi: 10.1093/nar/gkaa106

Figure Lengend Snippet: Quantification effects for different combination treatments. ( A ) Results of every linear elimination treatment, measured by Qubit. Plasmid (250 ng) and linear DNA (250 ng) were mixed, as templates (X, Mixture). Linear DNA (500 ng) (3-L, LIC-Lin) was set as control treatments. Every treatment had three replicates. 1-X, LRL-Mixture; 2-X, LRC-Mixture; 3-X, LIC-Mixture; 4-X, I+III-Mixture; 5-X, VIII4-Mixture; 6-X, VIIIC-Mixture. ( B ) The qPCR results from three exonuclease combination treatments (in accordance with Figure ). The primer BH2 was used across the plasmid BamHI site. Same quality (SQ): The Qubit amounts of qPCR input for all treatments were consistent (Supplemental S.1.2). Same volume (SV): The qPCR input volumes were consistent (Supplemental S.1.4 and ). P, pGL4.23 plasmid; L, linearized plasmid; X, Mixture; 3-P, LIC to cut plasmid; 3-L, LIC to cut linearized plasmid. Three experiments for each treatment were combined for enlarging the volume before purification. ( C ) The qPCR results correspond with Figure . The primer was BH2. Data are presented as mean ± SEM.

Article Snippet: After LRL (Lambda and RecJF within Lambda buffer) (NEB), LRC (Lambda and RecJF within Cutsmart buffer) (NEB), LIC (Lambda and Exonuclease I within Cutsmart buffer) (NEB) and I+IIIC (I+III or IIIIC) (Exonuclease I and Exonuclease III within Cutsmart buffer) (NEB) elimination, qPCR was performed.

Techniques: Plasmid Preparation, Purification

C-technology application and preliminary assessment in Hi-C. ( A ) DNA library (572 ng) linear noise elimination for C-technologies, after proximal-ligation. M (left), 1 kb DNA ladder; 1: LRL, LRL used for linear noise elimination. 2: LRC, LRC used for linear noise elimination; 3: LIC, LIC used for linear noise elimination; 4: I+IIIC, I+IIIC used for linear noise elimination; C: Co, without exonucleases digestion; M (right): 100 bp DNA ladder. ( B ) The yield ratio of remaining DNA after four linear elimination treatments, which was consistent to (A). The remaining ratio (gray) and eliminated ratio (purple) are shown together in the bar chart. ( C ) A 40 ng library was given four exonuclease treatment combinations, along with addition of plasmid chaperon carrier, as indicated. M: 1 kb + 100 bp DNA ladder. 1′: LRLP1, LRL with P1 chaperon used for linear noise elimination; 2′: LRC with P1 chaperon used for linear noise elimination; 3′: LICP1, LIC with P1 chaperon used for linear noise elimination; 4′: I+IIICP1, I+IIIC with P1 chaperon used for linear noise elimination; C’: P1 chaperon added, without exonucleases digestion. ( D ) The yield ratio of remaining DNA, after four linear DNA elimination treatments, which was consistent to ( C ). ( E ) HiC-Pro filtering results of Hi-C with exonuclease elimination LIC, compared with standard Hi-C in Figure . LIC-Hi-C had three experimental replicates (LIC-Hi-C 1; LIC-Hi-C 2; and LIC-Hi-C 3). HiC-Pro terms are as indicated in Supplemental S.3.

Journal: Nucleic Acids Research

Article Title: Exonuclease combinations reduce noises in 3D genomics technologies

doi: 10.1093/nar/gkaa106

Figure Lengend Snippet: C-technology application and preliminary assessment in Hi-C. ( A ) DNA library (572 ng) linear noise elimination for C-technologies, after proximal-ligation. M (left), 1 kb DNA ladder; 1: LRL, LRL used for linear noise elimination. 2: LRC, LRC used for linear noise elimination; 3: LIC, LIC used for linear noise elimination; 4: I+IIIC, I+IIIC used for linear noise elimination; C: Co, without exonucleases digestion; M (right): 100 bp DNA ladder. ( B ) The yield ratio of remaining DNA after four linear elimination treatments, which was consistent to (A). The remaining ratio (gray) and eliminated ratio (purple) are shown together in the bar chart. ( C ) A 40 ng library was given four exonuclease treatment combinations, along with addition of plasmid chaperon carrier, as indicated. M: 1 kb + 100 bp DNA ladder. 1′: LRLP1, LRL with P1 chaperon used for linear noise elimination; 2′: LRC with P1 chaperon used for linear noise elimination; 3′: LICP1, LIC with P1 chaperon used for linear noise elimination; 4′: I+IIICP1, I+IIIC with P1 chaperon used for linear noise elimination; C’: P1 chaperon added, without exonucleases digestion. ( D ) The yield ratio of remaining DNA, after four linear DNA elimination treatments, which was consistent to ( C ). ( E ) HiC-Pro filtering results of Hi-C with exonuclease elimination LIC, compared with standard Hi-C in Figure . LIC-Hi-C had three experimental replicates (LIC-Hi-C 1; LIC-Hi-C 2; and LIC-Hi-C 3). HiC-Pro terms are as indicated in Supplemental S.3.

Article Snippet: After LRL (Lambda and RecJF within Lambda buffer) (NEB), LRC (Lambda and RecJF within Cutsmart buffer) (NEB), LIC (Lambda and Exonuclease I within Cutsmart buffer) (NEB) and I+IIIC (I+III or IIIIC) (Exonuclease I and Exonuclease III within Cutsmart buffer) (NEB) elimination, qPCR was performed.

Techniques: Hi-C, Ligation, Plasmid Preparation